Scilex (NASDAQ:SCLX) Stock Price Down 1.2% – Here’s What Happened

Posted by Brenda Bartman on Aug 22nd, 2026

Scilex Holding Company (NASDAQ:SCLX – Get Free Report)’s share price was down 1.2% on Friday . The stock traded as low as $5.64 and last traded at $5.73. Approximately 25,993 shares traded hands during mid-day trading, a decline of 61% from the average session volume of 65,805 shares. The stock had previously closed at $5.80.

Analysts Set New Price Targets

Several research analysts recently issued reports on SCLX shares. Wall Street Zen raised Scilex from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Scilex in a research report on Tuesday, June 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Get Our Latest Research Report on SCLX

Scilex Trading Down 1.2%

The stock’s 50-day moving average price is $7.35 and its 200-day moving average price is $7.52. The stock has a market cap of $48.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.67.

Scilex (NASDAQ:SCLX – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($16.65) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($16.47). The firm had revenue of $7.64 million for the quarter, compared to the consensus estimate of $16.00 million.

Institutional Trading of Scilex

A number of large investors have recently bought and sold shares of SCLX. Goldman Sachs Group Inc. raised its position in shares of Scilex by 31.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 136,352 shares of the company’s stock worth $34,000 after acquiring an additional 32,449 shares in the last quarter. Norges Bank bought a new stake in shares of Scilex during the 2nd quarter valued at about $80,000. BNP Paribas Financial Markets boosted its position in shares of Scilex by 189.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,430 shares of the company’s stock valued at $146,000 after purchasing an additional 4,864 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Scilex during the fourth quarter worth approximately $150,000. Finally, XTX Topco Ltd acquired a new stake in Scilex during the fourth quarter worth approximately $249,000. 69.67% of the stock is currently owned by institutional investors and hedge funds.

Scilex Company Profile

(Get Free Report)

Scilex Holdings, Inc (NASDAQ: SCLX) is a specialty pharmaceutical company focused on non-opioid treatments for chronic pain. The firm’s principal commercial product, ZTlido®, is a lidocaine topical system approved by the U.S. Food and Drug Administration for the management of post-herpetic neuralgia and certain peripheral neuropathic pain conditions. By leveraging a proprietary drug delivery platform, Scilex aims to improve patient comfort and safety compared to traditional oral analgesics.

In addition to marketing ZTlido® in the United States, Scilex is advancing other pain management assets through clinical development and regulatory pathways.